Market Overview

Neuromyelitis Optica (Devic's Syndrome) | A Drug Pipeline Analysis Report 2018 | Technavio


Technavio has announced their latest drug pipeline analysis report on neuromyelitis
optica (Devic's syndrome)
. The report includes a detailed
analysis of the pipeline molecules under investigation within the
defined data collection period to treat neuromyelitis optica.

This press release features multimedia. View the full release here:

Technavio has published a new report on the drug development pipeline for neuromyelitis optica (Devi ...

Technavio has published a new report on the drug development pipeline for neuromyelitis optica (Devic's syndrome), including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the future.

This report is available at a USD 1,000 discount for a limited time
market snapshot before purchasing

Neuromyelitis optica (Devic's syndrome): Market

Neuromyelitis optica (NMO) – also known as NMO spectrum disorder,
Devic's disease, or Devic's syndrome – is a rare autoimmune disease that
mostly affects the optic nerves (optic neuritis) and the spinal cord
(myelitis). It occurs when the body's immune system attacks its own
cells in the central nervous system (CNS). Though the cause of NMO is
generally unknown, it can sometimes occur after an infection or can be
related to another autoimmune disease. NMO is different from multiple
sclerosis (MS). However, it is often misdiagnosed as MS.

According to a senior market research analyst at Technavio, "NMO can
lead to blindness in either one or both the eyes, loss of muscle
function in parts of the body, and painful spasms. It can also lead to
permanent visual loss and paralysis. The risk of NMO is higher in
African-Americans compared with Caucasians because of the heterogeneous
race. Companies are forming strategic exclusive licensing agreements or
acquiring companies to develop robust pipeline."

Neuromyelitis optica (Devic's syndrome):
Segmentation analysis

This drug pipeline analysis report segments the neuromyelitis optica
market based on therapies employed (monotherapy), RoA (oral,
subcutaneous, and IV), therapeutic modality (monoclonal antibody, small
molecule, autologous T-cell therapy, recombinant fusion proteins, and
synthetic cyclic peptide), targets for drug development (CD20 antigen,
aquaporin-4, AT-2 receptor, B lymphocyte receptor, CD19 antigen,
complement component 3, complement receptor, Fc receptor, interleukin-6,
monoacylglycerol lipase, nuclear receptor pathways, and serine/threonine
kinase-2), MoA (CD20 antigen inhibitor, aquaporin-4 reactive T-cell
inhibitor, AT-2 receptor stimulation, B lymphocyte receptor stimulator,
CD19 antigen inhibitor, complement component 3 inhibitor, complement
receptor inhibitor, Fc receptor inhibitor, immunosuppressants,
interleukin-17 stimulator, interleukin-6 inhibitor, monoacylglycerol
lipase inhibitor, potassium channel inhibitor, and serine/threonine
kinase-2 activator), geographical segmentation (US, UK, Italy, Japan,
Taiwan, and others) and recruitment status (active, not recruiting,
completed, enrolling by invitation, and recruiting). It provides an
in-depth analysis of the prominent factors influencing the market,
including drivers, opportunities, trends, and industry-specific

Based on therapeutic modality, more than 35% of the molecules that are
being investigated for the treatment of neuromyelitis optica are
monoclonal antibodies.

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team

View Comments and Join the Discussion!